Hepatocyte and Islet Cell Cotransplantation on Poly-L-Lactide Matrix for the Treatment of Liver Cirrhosis

Siufui Hendrawan, Jennifer Lheman, Nuraeni, Ursula Weber, Hans Ulrich Baer, Siufui Hendrawan, Jennifer Lheman, Nuraeni, Ursula Weber, Hans Ulrich Baer

Abstract

The human autologous hepatocyte matrix implant is a promising alternative procedure to counter liver damage. We assessed the outcome of human hepatocytes isolation from cirrhotic liver compared to the clinical and histological scores of disease severity. A total of 11 patients with various clinical scores (CTP and MELD) and histological score (Metavir, fibrosis) of liver cirrhosis were included in the hepatocyte matrix implant clinical phase I study. The liver segment and pancreatic tissue were harvested from each patient, and hepatocytes and cells of islets of Langerhans were isolated. The freshly isolated human hepatocytes were coseeded with the islet cells onto poly(l-lactic acid) (PLLA) scaffolds, cultured, and transplanted back into the patient. Human hepatocytes were isolated from 11 cirrhotic liver specimens with a resulting yield of 1.4 ± 0.5 × 106 cells per gram of the liver specimen and a viability rate of 52 ± 13%. It was found that the yield and viability of the liver cells were not correlated with the clinical and histological scores of the liver cirrhosis. A correlation was found between the hepatocyte yield obtained and the average number of hepatocytes counted in 10 microscopic fields of view. More viable cells were obtained from cirrhotic livers caused by chronic hepatitis B as compared to chronic hepatitis C in the same MELD score range. There was no correlation between the clinical and histological disease severity scores of liver cirrhosis and the outcome of hepatocytes isolation. It seems that the yield could depend on the type of hepatitis underlying the cirrhotic tissue. The study was registered at www.clinicaltrial.gov with the study identifier: NCT01335568.

Conflict of interest statement

We wish to confirm that there are no known conflicts of interest associated with this publication and there has been no significant financial support for this work that could have influenced its outcome.

Copyright © 2020 Siufui Hendrawan et al.

References

    1. Lee S.-W., Wang X., Chowdhury N. R., Roy-Chowdhury J. Hepatocyte transplantation: state of the art and strategies for overcoming existing hurdles. Annals of Hepatology. 2004;3(2):48–53. doi: 10.1016/S1665-2681(19)32108-8.
    1. Di Campli C., Nestola M., Piscaglia A. C., et al. Cell-based therapy for liver diseases. European Review for Medical and Pharmacological Sciences. 2003;7(2):41–44.
    1. Baer H. U., Hendrawan S., Suryadi T., et al. The intracorporeal autologous hepatocyte matrix implant for the treatment of chronic liver disease: a modified clinical phase I study. World J Surg Surg Res. 2018;1067(1)
    1. Kaufmann P. M., Kneser U., Fiegel H. C., et al. Is there an optimal concentration of cotransplanted islets of Langerhans for stimulation of hepatocytes in three dimensional matrices? Transplantation. 1999;68(2):272–279. doi: 10.1097/00007890-199907270-00020.
    1. Sugiyama K., Okamura A., Kawazoe N., Tateishi T., Sato S., Chen G. Coating of collagen on a poly(l-lactic acid) sponge surface for tissue engineering. Materials Science and Engineering: C. 2012;32(2):290–295. doi: 10.1016/j.msec.2011.10.031.
    1. Bhogal R. H., Hodson J., Bartlett D. C., et al. Isolation of primary human hepatocytes from normal and diseased liver tissue: a one hundred liver experience. PLoS One. 2011;6(3, article e18222) doi: 10.1371/journal.pone.0018222.
    1. Schwarz A., Lindl T., Höhneke C., Stange M., Pieken W. Human autologous liver cell transplantation for the treatment of cirrhosis. The Internet Journal of Gastroenterology. 2010;10(1) doi: 10.5580/456.
    1. Gramignoli R., Vosough M., Kannisto K., Srinivasan R. C., Strom S. C. Clinical hepatocyte transplantation: practical limits and possible solutions. European Surgical Research. 2015;54(3–4):162–177. doi: 10.1159/000369552.
    1. Fitzpatrick E., Wu Y., Dhadda P., et al. Coculture with mesenchymal stem cells results in improved viability and function of human hepatocytes. Cell Transplantation. 2015;24(1):73–83. doi: 10.3727/096368913X674080.
    1. Yimlamai D., Christodoulou C., Galli G. G., et al. Hippo pathway activity influences liver cell fate. Cell. 2014;157(6):1324–1338. doi: 10.1016/j.cell.2014.03.060.
    1. Yimlamai D., Fowl B. H., Camargo F. D. Emerging evidence on the role of the Hippo/YAP pathway in liver physiology and cancer. Journal of Hepatology. 2015;63(6):1491–1501. doi: 10.1016/j.jhep.2015.07.008.
    1. Mito M., Kusano M. Hepatocyte Transplantation in Man. Cell Transplantation. 2017;2(1):65–74. doi: 10.1177/096368979300200109.
    1. Soltys K. A., Soto-Gutiérrez A., Nagaya M., et al. Barriers to the successful treatment of liver disease by hepatocyte transplantation. Journal of Hepatology. 2010;53(4):769–774. doi: 10.1016/j.jhep.2010.05.010.
    1. Strom S., Chowdhury J., Fox I. Hepatocyte transplantation for the treatment of human disease. Seminars in Liver Disease. 1999;19(1):39–48. doi: 10.1055/s-2007-1007096.
    1. Lee C., Dhawan A., Filippi C., et al. Improving the efficacy of hepatocyte transplantation using alpha-1 antitrypsin as an immune modulator. Journal of Hepatology. 2018;68:S130–S131. doi: 10.1016/S0168-8278(18)30472-0.
    1. Johnson L. B., Aiken J., Mooney D., et al. The mesentery as a laminated vascular bed for hepatocyte transplantation. Cell Transplantation. 2017;3(4):273–281. doi: 10.1177/096368979400300403.
    1. Kneser U., Kaufmann P.-M., Fiegel H. C., et al. Interaction of hepatocytes and pancreatic islets cotransplanted in polymeric matrices. Virchows Archiv. 1999;435(2):125–132. doi: 10.1007/s004280050409.
    1. Török E., Lutgehetmann M., Bierwolf J., et al. Primary human hepatocytes on biodegradable poly(l-lactic acid) matrices: a promising model for improving transplantation efficiency with tissue engineering. Liver Transplantation. 2011;17(2):104–114. doi: 10.1002/lt.22200.
    1. Selden C., Hodgson H. Cellular therapies for liver replacement. Transplant Immunology. 2004;12(3–4):273–288. doi: 10.1016/j.trim.2003.12.008.
    1. Alexandrova K., Griesel C., Barthold M., et al. Large-scale isolation of human hepatocytes for therapeutic application. Cell Transplantation. 2017;14(10):845–853. doi: 10.3727/000000005783982530.
    1. Kawahara T., Toso C., Douglas D. N., et al. Factors affecting hepatocyte isolation, engraftment, and replication in an in vivo model. Liver Transplantation. 2010;16(8):974–982. doi: 10.1002/lt.22099.
    1. Richert L., Alexandre E., Lloyd T., et al. Tissue collection, transport and isolation procedures required to optimize human hepatocyte isolation from waste liver surgical resections. A multilaboratory study. Liver International. 2004;24(4):371–378. doi: 10.1111/j.1478-3231.2004.0930.x.
    1. Uyama S., Kaufmann P. M., Takeda T., Vacanti J. P. Delivery of whole liver-equivalent hepatocyte mass using polymer devices and hepatotrophic stimulation. Transplantation. 1993;55(4):932–935. doi: 10.1097/00007890-199304000-00044.
    1. European Association for the Study of the Liver. EASL clinical practical guidelines: Management of alcoholic liver disease. Journal of Hepatology. 2012;57(2):399–420. doi: 10.1016/j.jhep.2012.04.004.
    1. Mokdad A. A., Lopez A. D., Shahraz S., et al. Liver cirrhosis mortality in 187 countries between 1980 and 2010: a systematic analysis. BMC Medicine. 2014;12(1):p. 145. doi: 10.1186/s12916-014-0145-y.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe